Pneumocystis jirovecii pneumonia (PCP) is an important opportunistic infection in patients with autoimmune rheumatic diseases (AIRD), particularly those receiving high-dose glucocorticoids and other immunosuppressive therapies. The risk varies between rheumatic diseases and is influenced by the underlying disease, dose and duration of immunosuppression, and individual patient factors. Clinical presentation is often nonspecific, with fever, dry cough, dyspnea and hypoxemia, and delayed diagnosis may result in rapid deterioration. Early recognition, appropriate imaging and microbiological testing are therefore essential. Trimethoprim-sulfamethoxazole (TMP-SMX) remains the treatment of choice and the preferred agent for prophylaxis. Prophylaxis should be strongly considered when prednisone-equivalent doses of >20 mg/day are expected for >4 weeks, even in the absence of additional risk factors. Lower-dose TMP-SMX regimens may offer effective prophylaxis with better tolerability in selected patients.

Introduction

PCP was traditionally associated with advanced HIV infection, but it is now well recognized in patients receiving immunosuppressive treatment for AIRD. In rheumatology practice, it is particularly relevant during treatment of vasculitis, connective tissue diseases and inflammatory myopathies, when high-dose glucocorticoids may be combined with rituximab, cyclophosphamide or other immunosuppressive agents.

The diagnosis can be easily missed. Fever, dry cough, progressive breathlessness and fatigue may be attributed to infection, ILD or worsening of the underlying rheumatic disease. Once significant hypoxemia develops, deterioration can be rapid. A high index of suspicion is therefore important.

Who is at risk?

The risk of PCP varies substantially across AIRD. Granulomatosis with polyangiitis carries a considerably higher risk than conditions such as rheumatoid arthritis, systemic lupus erythematosus and idiopathic inflammatory myopathies. Prophylactic strategies should therefore be tailored to the disease rather than applied uniformly across all AIRD.

Glucocorticoid exposure is one of the major determinants of risk, with both dose and duration being important. The risk increases further when glucocorticoids are combined with rituximab, cyclophosphamide or other potent immunosuppressive therapies. Lymphopenia, older age, renal dysfunction, ILD and previous opportunistic infections may further increase risk.

Recognizing PCP

PCP usually develops over days to weeks. Fever, dry cough, progressive dyspnea and hypoxemia are common. Exertional desaturation may be an early clue even when resting oxygen saturation is relatively preserved.

Chest radiography may be normal early or show bilateral nonspecific infiltrates. HRCT is more sensitive and typically demonstrates bilateral ground-glass opacities, although these findings may also occur with viral infections, drug-induced pneumonitis or worsening ILD.

P. jirovecii PCR from induced sputum or bronchoalveolar lavage is widely used. Although highly sensitive, a positive PCR may represent colonization rather than active infection. Serum β-D-glucan can provide supportive evidence. Direct demonstration of the organism using stains such as Grocott-Gomori methenamine silver (GMS) or Giemsa can also aid diagnosis, particularly in induced sputum or bronchoalveolar lavage specimens.

When clinical suspicion is high, particularly with worsening hypoxemia, treatment should not necessarily be delayed while awaiting confirmation.

Treatment

TMP-SMX remains the treatment of choice. The usual treatment dose is 15–20 mg/kg/day of the trimethoprim component and 75–100 mg/kg/day of the sulfamethoxazole component, given in divided doses, for 14–21 days.

Renal function is important when prescribing TMP-SMX, particularly in patients with lupus or vasculitis with renal involvement. Dose adjustment may be required, with monitoring for hyperkalemia, cytopenias, renal dysfunction and hepatic toxicity.

Clindamycin-primaquine or intravenous pentamidine can be considered when TMP-SMX cannot be tolerated. In non-HIV PCP, adjunctive corticosteroids may be considered in patients with significant hypoxemia, particularly when PaO₂ is <70 mmHg on room air or the alveolar-arterial oxygen gradient is >35 mmHg.

Prophylaxis

A practical threshold for prophylaxis is prednisone-equivalent >20 mg/day for >4 weeks. At this level of steroid exposure, prophylaxis should be strongly considered even when no additional risk factors are present.

The indication is stronger when additional risk factors coexist. For example, a patient with granulomatosis with polyangiitis receiving high-dose glucocorticoids together with rituximab or cyclophosphamide would have a particularly high risk. Persistent lymphopenia, renal dysfunction, ILD and previous opportunistic infections should also lower the threshold for prophylaxis.

TMP-SMX is the preferred agent. Commonly used regimens include a single-strength tablet (80/400 mg) once daily or a double-strength tablet (160/800 mg) three times weekly. Lower-dose prophylaxis, such as TMP-SMX 80/400 mg three times weekly, has also been studied and may be useful in selected patients, particularly when standard dosing is poorly tolerated.

Renal function, blood counts, drug interactions and previous reactions to sulfonamides should be considered before starting prophylaxis. Hyperkalemia, cytopenias and renal dysfunction are the main adverse effects requiring attention.

When should prophylaxis be stopped?

The need for prophylaxis should be reviewed as immunosuppression is reduced. Steroid tapering is relevant, but it should not be the only consideration. Patients who continue to receive rituximab or other potent immunosuppressive therapy, or who have persistent lymphopenia or ILD, may remain at risk despite a reduction in steroid dose.

New respiratory symptoms should be evaluated promptly even in patients receiving prophylaxis, as PCP can occasionally occur despite preventive treatment.

Conclusion

PCP is an important and potentially preventable complication of immunosuppressive treatment in AIRD. Risk assessment should take into account the underlying disease, glucocorticoid exposure and concomitant immunosuppression.

For patients receiving >20 mg/day of prednisone or equivalent for >4 weeks, TMP-SMX prophylaxis should be strongly considered even in the absence of additional risk factors. In patients with high-risk diseases or additional factors such as rituximab or cyclophosphamide therapy, lymphopenia, renal dysfunction or ILD, prophylaxis may be appropriate at lower steroid doses.

Early recognition is equally important. Fever, dry cough, progressive dyspnea or unexplained hypoxemia in an immunosuppressed patient should prompt consideration of PCP rather than being attributed automatically to infection, ILD or a rheumatic disease flare. As immunosuppression changes, the need for prophylaxis should be reassessed.

References

1. Ohmura H. Pneumocystis jirovecii pneumonia in systemic rheumatic diseases: risk assessment and prophylaxis with emphasis on reduced-dose sulfamethoxazole/trimethoprim. Respir Investig. 2026;64(3):101436. doi:10.1016/j.resinv.2026.101436.

2. Park JW, Curtis JR, Kim MJ, Lee H, Song YW, Lee EB. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole. Arthritis Res Ther. 2019;21(1):207. doi:10.1186/s13075-019-1996-6.

3. Ohmura SI, Masui T, Yukishima T, Ohkubo Y, Yonezawa H, Miyamoto T. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in patients with systemic rheumatic diseases receiving moderate-to high-dose glucocorticoids. Respir Investig. 2024;62(6):1195-1201. doi:10.1016/j.resinv.2024.10.007.

4. Kim JY, Choi SR, Park JK, Lee EY, Lee EB, Park JW. Clinical factors associated with Pneumocystis pneumonia despite its primary prophylaxis: when to stop prophylaxis? Arthritis Rheumatol. 2025;77(9):1263-1272. doi:10.1002/art.43167.